Phillips, E., Bartlett, J. A., Sanne, I., Lederman, M. M., Hinkle, J., Rousseau, F., … Haas, D. W. (2013). Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr, 62(2), e55–e57. https://doi.org/10.1097/QAI.0b013e31827ca50f

Phillips, Elizabeth, John A. Bartlett, Ian Sanne, Michael M. Lederman, John Hinkle, Franck Rousseau, David Dunn, et al. “Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.” J Acquir Immune Defic Syndr 62, no. 2 (February 1, 2013): e55–57. https://doi.org/10.1097/QAI.0b013e31827ca50f.

Phillips E, Bartlett JA, Sanne I, Lederman MM, Hinkle J, Rousseau F, et al. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):e55–7.

Phillips, Elizabeth, et al. “Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.” J Acquir Immune Defic Syndr, vol. 62, no. 2, Feb. 2013, pp. e55–57. Pubmed, doi:10.1097/QAI.0b013e31827ca50f.

Phillips E, Bartlett JA, Sanne I, Lederman MM, Hinkle J, Rousseau F, Dunn D, Pavlos R, James I, Mallal SA, Haas DW. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):e55–e57.